Clal Biotechnology Industries

• MediWound MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on severe burn and chronic wound management

• Gamida Cell Gamida Cell is a cell and immune therapy visionary

• Gamida Cell's lead product, omidubicel, has recently successfully completed a phase III clinical trial in hematological malignancies
• Elicio Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer and infectious diseases

• Cadent Therapeutics Cadent Therapeutics is developing innovative drugs for neurological and psychiatric disorders

• This company has been recently acquired by Novartis
• Exithera eXIthera Pharmaceuticals is a clinical stage biotech company discovering and developing small molecule inhibitors of Factor XIa, which offer the potential of thrombosis prevention without the bleeding liabilities

• Biokine Biokine Therapeutics is developing novel therapeutics to treat cancer

• It's lead product, motixafortide (formerly BL-8040), is licensed to BiolineRx and is currently in phase III clinical development
• 27 DEC MediWound Strengthens European Presence of NexoBrid

MediWound Strengthens European Presence of NexoBrid

• 27 DEC MediWound Announces Positive Results in U
• S
• Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

• 26 DEC MediWound Strengthens European Presence of NexoBrid®

MediWound Strengthens European Presence of NexoBrid®

• 15 DEC MediWound Expands Global Presence as NexoBrid® Gains Approval in India

MediWound Expands Global Presence as NexoBrid® Gains Approval in India

• 12 DEC Gamida Cell Announces Closing of $25 Million Financing With Highbridge

Gamida Cell Announces Closing of $25 Million Financing With Highbridge

• 22 NOV Gamida Cell Provides Regulatory Update on Omidubicel

Gamida Cell Provides Regulatory Update on Omidubicel